ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sonidegib

Also written as “LDE225”, “Sonidegib Phosphate Capsules” and “LDE225+gemcitabine”.

Its studies are mostly in Medulloblastoma · Carcinoma, Basal Cell · Basal Cell Nevus Syndrome · Breast Neoplasms · Pancreatic Neoplasms, led by 2 companies.

Drug pageSonidegib: every studyAll 40 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Dec 15, 200916 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only150 open or runningphase 2since Dec 15, 2009Apr 9, 2009none ahead
Jemincare10 open or runningphase 4since Mar 12, 2025Mar 12, 2025none ahead

Also a collaborator on its studies: Sun Pharmaceutical Industries and Zhejiang Hangyu Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Jemincare only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 12, 2025First study: phase 4 study in CarcinomaFirst studyNCT06880848 · 160 enrolled · China

TargetBeta

SMO →read by rule
“Smoothened homolog inhibitor”ChEMBL 37, by rule

Other programs on SMO

ProgramCompanyFurthest phaseStudies
taladegibruleEli Lillyphase 211

Studies

The one study Jemincare leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06880848Carcinoma · China4CompletedAug 26, 2025160

How it is read

Names in the registry

  • “LDE225”, 12 entries
  • “Sonidegib Phosphate Capsules”, 1 entry
  • “LDE225+gemcitabine”, 1 entry
  • “Nilotinib + LDE225”, 1 entry
  • “LDE225 0.75%”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.